455 filings
6-K
HCM
HUTCHMED (China) Limited
17 May 24
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
10:02am
6-K
HCM
HUTCHMED (China) Limited
14 May 24
Current report (foreign)
7:13am
6-K
HCM
HUTCHMED (China) Limited
10 May 24
Annual General Meeting held on May 10, 2024 – Poll Results
8:16am
6-K
HCM
HUTCHMED (China) Limited
8 May 24
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
6:31am
6-K
HCM
HUTCHMED (China) Limited
29 Apr 24
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
6:14am
6-K
a3wxfx fcvdgq
22 Apr 24
Vesting of awards under the Long Term Incentive Plan
6:15am
6-K
baxmjhnzkhn07
8 Apr 24
Current report (foreign)
6:03am
6-K
dhvwmlo 6b
5 Apr 24
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
6:03am
6-K
assx1i5
2 Apr 24
Current report (foreign)
6:03am
6-K
peggh1hfx3z0v00o
28 Mar 24
Current report (foreign)
6:02am
6-K
p49zc4jp
22 Mar 24
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
6:06am
6-K
6wvovwgx84h
14 Mar 24
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
6:04am
6-K
clqy7b1 zmh4yu4dx04j
5 Mar 24
Vesting of awards under the Long Term Incentive Plan
6:04am
6-K
2ax1hf4hcvnqv40i41a
28 Feb 24
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
6:47am
6-K
eqobnsvk zaw
7 Feb 24
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
6:43am
6-K
losyhbog7uzo 8x
2 Feb 24
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
6:15am
6-K
ia37 tuzop
1 Feb 24
HUTCHMED to Announce 2023 Final Results
6:06am
6-K
06br032q4c2j dvpxt6
30 Jan 24
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
6:17am
6-K
iojgcav9kgc wjw93fy
11 Jan 24
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
6:02am